Dear Healthcare Professional,

Beginning on January 15, 2015, Somatuline® Depot will be available in an enhanced device incorporating Safe'n'Sound® syringe technology that is designed to improve the administration process for you and your patients. The device will offer multiple benefits:

- Retractable needle guard engages automatically to help avoid needle stick injuries
- Manufactured without latex or natural dry rubber
- Sturdy construction with a new plunger design

The device will continue to provide the following benefits:

- Prefilled, low-volume syringe supports full-dose delivery
- No reconstitution requirements
- Transparent syringe helps visually verify successful delivery



Somatuline Depot should be administered by a healthcare professional.

Indication

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Select Important Safety Information

CONTRAINDICATIONS

Somatuline is contraindicated in patients with hypersensitivity to lanreotide or related peptides.

WARNINGS AND PRECAUTIONS

- Somatuline may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed

Please see additional Important Safety Information throughout this letter and the accompanying full Prescribing Information.

Somatuline® Depot (lanreotide) Injection

Select Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

- Patients may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly
- Somatuline may decrease heart rate. In cardiac studies, the most common cardiac adverse reactions were sinus bradycardia, bradycardia, and hypertension. Dose adjustment of coadministered drugs that decrease heart rate may be necessary
- Somatuline may decrease bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted

ADVERSE REACTIONS

The most common adverse reactions (incidence >5%) were diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), constipation (8%), flatulence (7%), headache (7%), arthralgia (7%), vomiting (7%), and loose stools (6%).

USE IN SPECIFIC POPULATIONS

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment: Initial dose is 60 mg every 4 weeks.

Please see accompanying full Prescribing Information.

We look forward to introducing the enhanced device to you and your patients.

For more information, visit ***www.SomatulineDepot.com***

ORDERING INFORMATION

Description	NDC Code
60 mg, prefilled syringe	15054-0060-3
90 mg, prefilled syringe	15054-0090-3
120 mg, prefilled syringe	15054-0120-3

Available January 15, 2015

For information relating to safety, please call (888) 980-2889.

For 1-on-1 support, contact the IPSEN CARES (IPSEN Coverage, Access, Reimbursement & Education Support) program by calling (866) 435-5677.

IPSEN
Innovation for patient care

Somatuline® Depot
(lanreotide) Injection